Safety and Pharmacokinetics of Kovacaine Nasal Spray (24 Hour Blood Collection)
Condition: Anesthesia
Intervention: Tetracaine HCl 3% and Oxymetazoline HCl 0.05%
Intervention description: 1 spray is 0.2mL is volume and contains 6mg Tetracaine HCl 3% and 0.1mg Oxymetazoline HCl (para-butylaminobenzoic acid or PABA is active metabolite)
Intervention MeSH terms: Phenylephrine; Oxymetazoline; Tetracaine
Phase: Phase 2
Study type: Interventional
Primary purpose: Treatment
Intervention model: Single Group Assignment
Masking: None (Open Label)
Enrollment: 24.0
Sex: All
Minimum age: 18 Years
Maximum age: 75 Years
Healthy volunteers: Accepts Healthy Volunteers
Keywords: Pharmacokinetic

Summary:

      The purpose of this study is to determine the pharmacokinetics/pharmacodynamics and safety of
      a nasal spray containing the anesthetic drug tetracaine in combination with oxymetazoline
      with blood draws over 24 hours.
    

Eligibility criteria:

        Inclusion Criteria:

          -  Male or non-pregnant, non-breast-feeding female subjects between the ages of 18 and 75
             years (inclusive).

          -  Can understand and sign the informed consent document, can communicate with the
             investigator, and can understand and comply with the requirements of the protocol.

          -  Body mass index between 18 and 35 BMI.

          -  Sufficiently healthy as determined by the investigator to receive the test medications
             and undergo the scheduled study procedure.

          -  Can breathe through both nostrils.

          -  Screening BP ≤ 140/90 mm Hg.

        Exclusion Criteria:

          -  History of clinically significant respiratory, gastrointestinal, renal, hepatic,
             neurologic, hematologic, endocrine, oncologic, pulmonary, immunologic, psychiatric, or
             cardiovascular disease, including cardiac arrhythmia, narrow angle glaucoma and benign
             prostatic hypertrophy (in men), uncontrolled thyroid disease (including Hashimoto's
             Thyroiditis and lymphocytic thyroiditis), uncontrolled diabetes mellitus or any other
             condition which, in the opinion of the Principal Investigator, would jeopardize the
             safety of the subject or impact the validity of the study results.

          -  Has clinically significant abnormal findings on the physical examination, medical
             history, electrocardiogram (ECG), or clinical laboratory evaluation during screening.
             This includes current upper respiratory infections.

          -  Currently experiencing seasonal or perennial allergic rhinitis, recurrent nose-bleeds
             or asthma, or has a significant history of these conditions, in the opinion of the
             Investigator.

          -  Current, including the last 30 days, sinusitis or other upper respiratory infections.

          -  Nasal polyps, significant nasal or sinus surgery or other abnormality that may
             interfere with the dose administration.

          -  History of allergic or adverse responses to tetracaine, other ester local anesthetics,
             PBBA, oxymetazoline and its preservatives, or para-aminobenzoic acid as found in PABA
             containing sunscreens or any comparable or similar product.

          -  Donation of blood or plasma within 30 days of the first dose of Study Drug.

          -  Participation in a clinical trial within 30 days prior to the first dose of Study
             Drug.

          -  Use of any new over-the-counter (OTC) medication, including topical anesthetic creams
             or gels, vitamins, within seven days prior to the first dose of the Study Drug or
             during the study unless approved by the Principal Investigator.

          -  Any prescription medication, whose dose is not stable at the time of screening, as
             determined by the Principal Investigator.

          -  Treatment with any known enzyme altering drugs such as barbiturates, phenothiazines,
             cimetidine, carbamazepine, etc., within 30 days prior to the first dose of Study Drug
             or during the study.

          -  Smoking or use of tobacco products within 6 months prior to the first dose of Study
             Drug or during the study.

          -  Female trying to conceive, is pregnant, suspected of being pregnant, or is lactating.
             (Females of child-bearing potential will be required to take a serum pregnancy test at
             screening (up to 21 days prior to the start of the study, including the day of the
             study), as well as a urine pregnancy test at check-in to rule out pregnancy.)

          -  Positive serum pregnancy test at screening or urine pregnancy test at check-in for all
             women of childbearing potential.

          -  Positive blood screen for HIV, Hepatitis B surface antigen (HbSAg), or Hepatitis C, or
             a positive urine screen for alcohol, drugs of abuse, or cotinine.

          -  Have a history of pseudocholinesterase deficiency or previous prolonged paralysis with
             succinylcholine or difficulty waking up from general anesthesia.

          -  Have a history of alcoholism and/or drug abuse.

          -  Have taken a monoamine oxidase inhibitor or vasopressor drug within the past 3 weeks.